Stocks › ELV
Elevance Health, Inc.
ELV·NYSE·
United States·USD
United States·USD$400.09
+5.58 (+1.41%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
ELV
Elevance Health, Inc. · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ELVS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ELV by members of U.S. Congress · 99 on record · 10 in the last 12 months
Whale Activity
Position changes in ELV reported for 2026-09-30 by 2 tracked institutional filers
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| ROCKLAND TRUST CO | 69.1K | $26.9M | — |
| BRIGHT ROCK CAPITAL MANAGEMENT, LLC | 21.0K | $8.2M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ELV insiders, by quarter · Form 4
Recent Insider Transactions
222 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| BOUDREAUX GAILPresident and CEO · Director | Purchase | +680 | $366.41 | $249K | Jul 17, 2026 | Form 4 ↗ |
| BOUDREAUX GAILPresident and CEO · Director | Purchase | +2,045 | $368.25 | $753K | Jul 17, 2026 | Form 4 ↗ |
| PERU RAMIRO GDirector · Director | Purchase | +1,000 | $366.05 | $366K | Jul 17, 2026 | Form 4 ↗ |
| Penczek Ronald WCAO & Controller | Sale | −369 | $403.16 | $149K | Jun 12, 2026 | Form 4 ↗ |
| Dixon Robert L JRDirector | Sale | −151 | $401.77 | $61K | Jun 11, 2026 | Form 4 ↗ |
| Penczek Ronald WCAO & Controller | Sale | −1,531 | $403.13 | $617K | May 19, 2026 | Form 4 ↗ |
| Penczek Ronald WCAO & Controller | Option exercise | +877 | $311.48 | $273K | May 19, 2026 | Form 4 ↗ |
| Penczek Ronald WCAO & Controller | Option exercise | +654 | $271.27 | $177K | May 19, 2026 | Form 4 ↗ |
| Jallal BahijaDirector | Grant / award | +563 | $0.00 | $0 | May 13, 2026 | Form 4 ↗ |
| Neri Antonio FDirector | Grant / award | +563 | $0.00 | $0 | May 13, 2026 | Form 4 ↗ |
| STRABLE-SOETHOUT DEANNA DDirector | Grant / award | +563 | $0.00 | $0 | May 13, 2026 | Form 4 ↗ |
| DeVore Susan D.Director | Grant / award | +563 | $0.00 | $0 | May 13, 2026 | Form 4 ↗ |
| Dixon Robert L JRDirector | Grant / award | +563 | $0.00 | $0 | May 13, 2026 | Form 4 ↗ |
| SCHULMAN AMY WDirector | Grant / award | +563 | $0.00 | $0 | May 13, 2026 | Form 4 ↗ |
| Schneider Ryan M.Director | Grant / award | +563 | $0.00 | $0 | May 13, 2026 | Form 4 ↗ |
| PERU RAMIRO GDirector | Grant / award | +563 | $0.00 | $0 | May 13, 2026 | Form 4 ↗ |
| COLLIS STEVEN HDirector | Grant / award | +563 | $0.00 | $0 | May 13, 2026 | Form 4 ↗ |
| HAY LEWIS IIIDirector | Grant / award | +563 | $0.00 | $0 | May 13, 2026 | Form 4 ↗ |
| SCHULMAN AMY WDirector | Sale | −26 | $287.50 | $7K | Mar 12, 2026 | Form 4 ↗ |
| Kendrick Charles Morgan JREVP & President, Commercial | Sale | −3,196 | $284.92 | $911K | Mar 6, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ELV · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 6.6M | $2.56B | 0.11% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 5.4M | $2.08B | 0.12% | Jun 30, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 3.0M | $1.16B | 0.13% | Jun 30, 2026 |
| VANGUARD WINDSOR II FUND VANGUARD WINDSOR FUNDS | 3.0M | $1.14B | 1.71% | Jul 31, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 2.8M | $1.11B | 0.13% | May 31, 2026 |
| First Eagle Global Fund First Eagle Funds | 2.8M | $1.07B | 1.41% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 2.6M | $1.02B | 0.13% | Jun 30, 2026 |
| VANGUARD EQUITY INCOME FUND VANGUARD FENWAY FUNDS | 2.0M | $791.3M | 1.21% | Jun 30, 2026 |
| VANGUARD VALUE INDEX FUND VANGUARD INDEX FUNDS | 2.0M | $782.5M | 0.31% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 1.9M | $698.4M | 1.83% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ELV's shares (CUSIP 036752103), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming elevance health as client
- CONTINENTAL STRATEGY, LLCELEVANCE HEALTH · 2025 Q3 · HCR$75K
Filing ↗ - CAPITOL HILL CONSULTING GROUPELEVANCE HEALTH, INC · 2026 Q2 · MMM, HCR$60K
Filing ↗ - ELEVANCE HEALTH, INC.ELEVANCE HEALTH, INC. · 2026 Q2 · HCR, MMM, INS, PHA$2.3M
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCELEVANCE HEALTH, INC (F.K.A. ANTHEM, INC. & WELLPOINT, INC.) · 2026 Q2 · BUD, HCR, MMM, VET$80K
Filing ↗ - CONTINENTAL STRATEGY, LLCELEVANCE HEALTH · 2026 Q2 · HCR$75K
Filing ↗
Government Contracts
Federal awards to Elevance Health, Inc. · USAspending
No federal contract awards found for Elevance Health, Inc..
U.S. Patents
Recent USPTO applications naming Elevance Health, Inc.
No USPTO patent applications found for Elevance Health, Inc..
Annual Financials
From ELV's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $199.13B | $177.01B | $171.34B | $156.59B | $138.64B |
| Operating income | $7.20B | $7.86B | $8.50B | $8.28B | $7.56B |
| Net income | $5.66B | $5.98B | $5.99B | $5.89B | $6.16B |
| Diluted EPS | $25.21 | $25.68 | $25.22 | $24.28 | $24.95 |
| Operating cash flow | $4.29B | $5.81B | $8.06B | $8.40B | $8.36B |
| Cash and equivalents | $9.49B | $8.29B | $6.53B | $7.39B | $4.88B |
| Total assets | $121.49B | $116.89B | $108.93B | $102.75B | $97.46B |
| Total liabilities | $77.47B | $75.46B | $69.52B | $66.42B | $61.33B |
| Shareholders' equity | $43.88B | $41.31B | $39.31B | $36.24B | $36.06B |
As Elevance Health, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 6, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitJun 1, 2005
Split dates and ratios from the price history · Close Prices from Tiingo.com
About Elevance Health, Inc.
From SEC EDGAR company records
Industry (SIC 6324)Hospital & Medical Service Plans
SectorFinancials
HeadquartersINDIANAPOLIS, IN
IncorporatedIN
SEC CIK0001156039 ↗
Former namesAnthem, Inc., WELLPOINT, INC, WELLPOINT INC